Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Saudi Pharmaceutical Industries & Medical Appliances EBITDA Margin % Related Terms
Saudi Pharmaceutical Industries & Medical Appliances EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saudi Pharmaceutical Industries & Medical Appliances EBITDA Margin % Chart
Saudi Pharmaceutical Industries & Medical Appliances Annual Data
SAU:2070 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Saudi Pharmaceutical Industries & Medical Appliances's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saudi Pharmaceutical Industries & Medical Appliances EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) has a EBITDA Margin % of 28.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Saudi Pharmaceutical Industries & Medical Appliances and its competitors. This is 127% above median its historical median of 12.54. According to the industry distribution chart, Saudi Pharmaceutical Industries & Medical Appliances ranks #217 out of 952 companies in the Drug Manufacturers industry, placing it in the top 22.8%.
Is Saudi Pharmaceutical Industries & Medical Appliances' EBITDA Margin % too high?
Saudi Pharmaceutical Industries & Medical Appliances' current EBITDA Margin % of 28.42% is 127% above median its 10-year median of 12.54. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Saudi Pharmaceutical Industries & Medical Appliances' value of 28.42% is 127.9% above this industry median. Based on the distribution chart, Saudi Pharmaceutical Industries & Medical Appliances ranks #217 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Saudi Pharmaceutical Industries & Medical Appliances has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Saudi Pharmaceutical Industries & Medical Appliances' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Saudi Pharmaceutical Industries & Medical Appliances ranks #217 out of 952 companies for EBITDA Margin %. This places Saudi Pharmaceutical Industries & Medical Appliances in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Saudi Pharmaceutical Industries & Medical Appliances' value of 28.42% is 127.9% above this benchmark. While the company's 10-year median is 12.54 vs. the industry median of 12.47, Saudi Pharmaceutical Industries & Medical Appliances has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saudi Pharmaceutical Industries & Medical Appliances's current EBITDA Margin % of 28.42% is 127.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Saudi Pharmaceutical Industries & Medical Appliances and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saudi Pharmaceutical Industries & Medical Appliances's current EBITDA Margin % is 28.42%, which is 127% above median its own 10-year median of 12.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saudi Pharmaceutical Industries & Medical Appliances stock overvalued right now?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) is currently considered Fairly Valued. The stock's GF Value™ is ﷼31.13, compared to a current price of ﷼28.58 — trading 8.2% below its estimated fair value. The current EBITDA Margin % is 28.42%, which is 127% above median its 10-year median of 12.54 and 127.9% above the Drug Manufacturers industry median of 12.47. Saudi Pharmaceutical Industries & Medical Appliances' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070), the current EBITDA Margin % is 28.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saudi Pharmaceutical Industries & Medical Appliances (SAU:2070) Overvalued in 2026?
Based on GuruFocus' analysis, Saudi Pharmaceutical Industries & Medical Appliances stock appears to be undervalued.
The current stock price of ﷼28.58 is trading 8.2% below its estimated GF Value™ of ﷼31.13.
GuruFocus considers Saudi Pharmaceutical Industries & Medical Appliances to be Fairly Valued.
Key valuation signals for SAU:2070:
EBITDA Margin %: 28.42% (127% above median its 10-year median of 12.54)
GF Value™: ﷼31.13 vs. price of ﷼28.58 (8.2% below fair value)
Industry Position: 127.9% above the Drug Manufacturers median (#217 of 952)
No single metric tells the full story. See the SAU:2070 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saudi Pharmaceutical Industries & Medical Appliances Business Description
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
73GF Score
Get the complete analysis for SAU:2070
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:2070 has been successfully added to your 
